Matching articles for "Xtandi"

Talazoparib (Talzenna) for Prostate Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • August 7, 2023;  (Issue 1682)
The oral poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib (Talzenna – Pfizer) has been approved by the FDA for use in combination with the androgen receptor blocker enzalutamide (Xtandi)...
The oral poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib (Talzenna – Pfizer) has been approved by the FDA for use in combination with the androgen receptor blocker enzalutamide (Xtandi) for treatment of adults with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). The drug has been available since 2018 for treatment of deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative locally advanced or metastatic breast cancer.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):e134-5 | Show Full IntroductionHide Full Introduction

In Brief: A New Prostate Cancer Indication for Olaparib (Lynparza) (online only)

   
The Medical Letter on Drugs and Therapeutics • June 26, 2023;  (Issue 1679)
The oral poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza – AstraZeneca) has now been approved by the FDA for use in combination with abiraterone (Zytiga, and others) and either prednisone...
The oral poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza – AstraZeneca) has now been approved by the FDA for use in combination with abiraterone (Zytiga, and others) and either prednisone or prednisolone for treatment of adults with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). Olaparib was previously approved by the FDA for treatment of adults with deleterious or suspected deleterious germline or somatic homologous recombinant repair (HRR) genemutated mCRPC who progressed on prior treatment with enzalutamide (Xtandi) or abiraterone.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):e106-7 | Show Full IntroductionHide Full Introduction

Darolutamide (Nubeqa) for Prostate Cancer

   
The Medical Letter on Drugs and Therapeutics • December 16, 2019;  (Issue 1587)
The FDA has approved darolutamide (Nubeqa – Bayer), an androgen receptor inhibitor, for oral treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC). Darolutamide is the third androgen...
The FDA has approved darolutamide (Nubeqa – Bayer), an androgen receptor inhibitor, for oral treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC). Darolutamide is the third androgen receptor inhibitor to be approved for this indication; apalutamide (Erleada) and enzalutamide (Xtandi), which are also approved for use in patients with metastatic castration-resistant prostate cancer (mCRPC), were approved earlier.
Med Lett Drugs Ther. 2019 Dec 16;61(1587):201-2 | Show Full IntroductionHide Full Introduction

Apalutamide (Erleada) for Prostate Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • July 16, 2018;  (Issue 1551)
Apalutamide (Erleada – Janssen) has received accelerated approval from the FDA for treatment of nonmetastatic castration-resistant prostate cancer. It is the first drug to be approved in the US for...
Apalutamide (Erleada – Janssen) has received accelerated approval from the FDA for treatment of nonmetastatic castration-resistant prostate cancer. It is the first drug to be approved in the US for this indication. Apalutamide is an oral antiandrogen that binds to the ligand-binding domain of the androgen receptor.
Med Lett Drugs Ther. 2018 Jul 16;60(1551):e124-5 | Show Full IntroductionHide Full Introduction

Radium-223 (Xofigo) for Prostate Cancer

   
The Medical Letter on Drugs and Therapeutics • September 30, 2013;  (Issue 1426)
Radium Ra 223 dichloride (Xofigo – Bayer), a radiotherapeutic drug, has been approved by the FDA for intravenous treatment of castration-resistant prostate cancer with symptomatic bone metastases and...
Radium Ra 223 dichloride (Xofigo – Bayer), a radiotherapeutic drug, has been approved by the FDA for intravenous treatment of castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease.
Med Lett Drugs Ther. 2013 Sep 30;55(1426):79-80 | Show Full IntroductionHide Full Introduction

Enzalutamide (Xtandi) for Prostate Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • March 4, 2013;  (Issue 1411)
The FDA has approved enzalutamide (en za loo’ ta mide; Xtandi – Astellas/Medivation) for oral treatment of metastatic castration-resistant prostate cancer in patients previously treated with docetaxel...
The FDA has approved enzalutamide (en za loo’ ta mide; Xtandi – Astellas/Medivation) for oral treatment of metastatic castration-resistant prostate cancer in patients previously treated with docetaxel (Taxotere, and generics). It is the second oral drug approved for this indication; abiraterone acetate (Zytiga), which is also approved for first-line use, was the first. Cabazitaxel (Jevtana), which is given parenterally, has a similar indication.
Med Lett Drugs Ther. 2013 Mar 4;55(1411):20 | Show Full IntroductionHide Full Introduction